Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis

Alessandro Mantovani,Giorgia Beatrice,Andrea Dalbeni
DOI: https://doi.org/10.1111/liv.14465
IF: 8.754
2020-04-24
Liver International
Abstract:<p>At present, there is scarce information regarding the global prevalence of chronic liver disease in individuals with COVID‐19 disease, which is become a global pandemic early. Aim of this study was to assess the overall prevalence of chronic liver disease among patients with COVID‐19 disease by meta‐analyzing data in observational studies and to investigate the relationship between liver damage and COVID‐19 disease. We included 11 observational studies for a total of 2,034 adult individuals (median age 49 years [IQR 45‐54], 57.2% men). The overall prevalence of chronic liver disease at baseline was 3% (95% CI 2‐4%; I<sup>2</sup>=29.1%). Individuals with severe COVID‐19 disease had relevant alterations of liver enzymes and coagulative profile, probably due to the innate immune response against the virus. Further studies are needed to better investigate the causes of liver injury in patients with COVID‐19 disease and the effect of treatment for COVID‐19 on the liver.</p>
gastroenterology & hepatology
What problem does this paper attempt to address?